ArticleEmerging microbes & infections2022
Effective phage cocktail to combat the rising incidence of extensively drug-resistant
Article in Emerging microbes & infections, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Evolutionary dynamics and research hotspots of phage applications againstFrontiers in microbiology · 2026Pooled it
- Phage anti-defense genes targeting NADVirulence · 2026Article
- Synergistic Antibacterial and Antibiofilm Effects of (KW)Journal of peptide science : an official publication of the European Peptide Society · 2026Article
- Helicobacter pylori phages: resource landscape, translational challenges, and engineered antibacterial strategies.Archives of microbiology · 2026Review
- Phage Therapy in Combating Multidrug-Resistant Gram-Negative Pathogens: A Scoping Review.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Prevalence, Virulence, and Pathogenic Mechanisms of Mastitis-AssociatedVeterinary sciences · 2026Review
- Systematic evaluation of phage cocktail-ciprofloxacin combination therapy against multidrug-resistantMicrobiology spectrum · 2026Article
- A novel phage preparation capable of simultaneously inhibiting both K1 and K2 serotypes ofApplied and environmental microbiology · 2026Article
- Isolation and characterization of lytic bacteriophages with therapeutic potential against multidrug resistant Klebsiella pneumoniae from Ethiopia.Scientific reports · 2026Article
- Stevioside curbs Streptococcus pneumoniae infection via inhibiting capsule biosynthesis.Communications biology · 2026Article
- Colanic acid-mediated phage resistance enhances virulence in high-risk global clone Escherichia coli ST410.PLoS pathogens · 2025Article
- Evolving strategies of intracellular HypervirulentVirulence · 2025Article
- Identification and preclinical efficacy evaluation of two lytic bacteriophages targeting highly virulent and multidrug-resistant Klebsiella pneumoniae.Annals of clinical microbiology and antimicrobials · 2025Article
- StudiesAntimicrobial agents and chemotherapy · 2025Article
- Capsule mutations serve as a key strategy of phage resistance evolution of K54 hypervirulent Klebsiella pneumoniae.Communications biology · 2025Article
- Bacteriophage therapy: a possible alternative therapy against antibiotic-resistant strains ofFrontiers in microbiology · 2025Review
- Article
- Isoferulic acid facilitates effective clearance of hypervirulent Klebsiella pneumoniae through targeting capsule.PLoS pathogens · 2025Article
- A Klebsiella-phage cocktail to broaden the host range and delay bacteriophage resistance both in vitro and in vivo.NPJ biofilms and microbiomes · 2024Article
- Antibacterial effect of phage cocktails and phage-antibiotic synergy against pathogenicmSystems · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bacteriophages are the most abundant organisms on Earth. As there are few effective treatment options against some pathogens, the interest in the bacteriophage control of multi-drug-resistant bacterial pathogens is escalating, especially for
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.